232 related articles for article (PubMed ID: 28068312)
21. Catalytic mechanism of MraY and WecA, two paralogues of the polyprenyl-phosphate N-acetylhexosamine 1-phosphate transferase superfamily.
Al-Dabbagh B; Olatunji S; Crouvoisier M; El Ghachi M; Blanot D; Mengin-Lecreulx D; Bouhss A
Biochimie; 2016 Aug; 127():249-57. PubMed ID: 27312048
[TBL] [Abstract][Full Text] [Related]
22. Structural requirement of tunicamycin V for MraY inhibition.
Yamamoto K; Katsuyama A; Ichikawa S
Bioorg Med Chem; 2019 Apr; 27(8):1714-1719. PubMed ID: 30850266
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis.
Kimura K; Bugg TD
Nat Prod Rep; 2003 Apr; 20(2):252-73. PubMed ID: 12735700
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of action of nucleoside antibacterial natural product antibiotics.
Bugg TDH; Kerr RV
J Antibiot (Tokyo); 2019 Dec; 72(12):865-876. PubMed ID: 31471595
[TBL] [Abstract][Full Text] [Related]
25. Crystal structure of MraY, an essential membrane enzyme for bacterial cell wall synthesis.
Chung BC; Zhao J; Gillespie RA; Kwon DY; Guan Z; Hong J; Zhou P; Lee SY
Science; 2013 Aug; 341(6149):1012-1016. PubMed ID: 23990562
[TBL] [Abstract][Full Text] [Related]
26. Modes of action of tunicamycin, liposidomycin B, and mureidomycin A: inhibition of phospho-N-acetylmuramyl-pentapeptide translocase from Escherichia coli.
Brandish PE; Kimura KI; Inukai M; Southgate R; Lonsdale JT; Bugg TD
Antimicrob Agents Chemother; 1996 Jul; 40(7):1640-4. PubMed ID: 8807054
[TBL] [Abstract][Full Text] [Related]
27. Chemical logic of MraY inhibition by antibacterial nucleoside natural products.
Mashalidis EH; Kaeser B; Terasawa Y; Katsuyama A; Kwon DY; Lee K; Hong J; Ichikawa S; Lee SY
Nat Commun; 2019 Jul; 10(1):2917. PubMed ID: 31266949
[TBL] [Abstract][Full Text] [Related]
28. Active site mapping of MraY, a member of the polyprenyl-phosphate N-acetylhexosamine 1-phosphate transferase superfamily, catalyzing the first membrane step of peptidoglycan biosynthesis.
Al-Dabbagh B; Henry X; El Ghachi M; Auger G; Blanot D; Parquet C; Mengin-Lecreulx D; Bouhss A
Biochemistry; 2008 Aug; 47(34):8919-28. PubMed ID: 18672909
[TBL] [Abstract][Full Text] [Related]
29. Natural Products at Work: Structural Insights into Inhibition of the Bacterial Membrane Protein MraY.
Koppermann S; Ducho C
Angew Chem Int Ed Engl; 2016 Sep; 55(39):11722-4. PubMed ID: 27511599
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and Medicinal Chemistry of Muraymycins, Nucleoside Antibiotics.
Katsuyama A; Ichikawa S
Chem Pharm Bull (Tokyo); 2018; 66(2):123-131. PubMed ID: 29386462
[TBL] [Abstract][Full Text] [Related]
31. Total Synthesis of Dansylated Park's Nucleotide for High-Throughput MraY Assays.
Wohnig S; Spork AP; Koppermann S; Mieskes G; Gisch N; Jahn R; Ducho C
Chemistry; 2016 Dec; 22(49):17813-17819. PubMed ID: 27791327
[TBL] [Abstract][Full Text] [Related]
32. Muraymycin Nucleoside Antibiotics: Structure-Activity Relationship for Variations in the Nucleoside Unit.
Heib A; Niro G; Weck SC; Koppermann S; Ducho C
Molecules; 2019 Dec; 25(1):. PubMed ID: 31861655
[TBL] [Abstract][Full Text] [Related]
33. Development of a natural product optimization strategy for inhibitors against MraY, a promising antibacterial target.
Yamamoto K; Sato T; Hao A; Asao K; Kaguchi R; Kusaka S; Ruddarraju RR; Kazamori D; Seo K; Takahashi S; Horiuchi M; Yokota SI; Lee SY; Ichikawa S
Nat Commun; 2024 Jun; 15(1):5085. PubMed ID: 38877016
[TBL] [Abstract][Full Text] [Related]
34. Elucidating the Structural Requirement of Uridylpeptide Antibiotics for Antibacterial Activity.
Terasawa Y; Sataka C; Sato T; Yamamoto K; Fukushima Y; Nakajima C; Suzuki Y; Katsuyama A; Matsumaru T; Yakushiji F; Yokota SI; Ichikawa S
J Med Chem; 2020 Sep; 63(17):9803-9827. PubMed ID: 32787111
[TBL] [Abstract][Full Text] [Related]
35. Ligand Shaping in Induced Fit Docking of MraY Inhibitors. Polynomial Discriminant and Laplacian Operator as Biological Activity Descriptors.
Lungu CN; Diudea MV; Putz MV
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28653980
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and conformation-activity relationship analysis of LNA/BNA-type 5'-O-aminoribosyluridine as MraY inhibitors.
Kusaka S; Yamamoto K; Shinohara M; Minato Y; Ichikawa S
Bioorg Med Chem; 2022 Jul; 65():116744. PubMed ID: 35500521
[TBL] [Abstract][Full Text] [Related]
37. Lipid Requirements for the Enzymatic Activity of MraY Translocases and in Vitro Reconstitution of the Lipid II Synthesis Pathway.
Henrich E; Ma Y; Engels I; Münch D; Otten C; Schneider T; Henrichfreise B; Sahl HG; Dötsch V; Bernhard F
J Biol Chem; 2016 Jan; 291(5):2535-46. PubMed ID: 26620564
[TBL] [Abstract][Full Text] [Related]
38. A high-throughput, homogeneous, fluorescence resonance energy transfer-based assay for phospho-N-acetylmuramoyl-pentapeptide translocase (MraY).
Shapiro AB; Jahić H; Gao N; Hajec L; Rivin O
J Biomol Screen; 2012 Jun; 17(5):662-72. PubMed ID: 22337656
[TBL] [Abstract][Full Text] [Related]
39. Identification of a novel inhibition site in translocase MraY based upon the site of interaction with lysis protein E from bacteriophage ϕX174.
Rodolis MT; Mihalyi A; O'Reilly A; Slikas J; Roper DI; Hancock RE; Bugg TD
Chembiochem; 2014 Jun; 15(9):1300-8. PubMed ID: 24895118
[TBL] [Abstract][Full Text] [Related]
40. Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I.
Siricilla S; Mitachi K; Skorupinska-Tudek K; Swiezewska E; Kurosu M
Anal Biochem; 2014 Sep; 461():36-45. PubMed ID: 24939461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
